Lillian Siu
机构: Princess Margaret Cancer Centre
每年引用次数
引用次数
引用: 43,648
H-指数: 106
I10-指数 : 427
出版物: 1,049
P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.
Victoria Mandilaras , Swati Garg , Julia Burnier , Katherine Karakasis
Journal of Clinical Oncology 34 5550 -5550
2016
Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.
Victoria Mandilaras , Stephanie Lheureux , Neda Stjepanovic , Julia Burnier
Journal of Clinical Oncology 34 5579 -5579
2016
Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).
Ricard Mesia , Paolo Bossi , Aaron Richard Hansen , Ching-Yun Hsieh
Journal of Clinical Oncology 34 6029 -6029
1
2016
Systemic therapies for recurrent/metastatic nasopharyngeal carcinoma (RM NPC).
Amy Prawira , Sjoukje Oosting , Tom Wei-Wu Chen , Ronak Saluja
Journal of Clinical Oncology 34 6031 -6031
3
2016
Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.
Shelly Sud , Christopher J O'Callaghan , Christos Stelios Karapetis , Caleb Jonker
Journal of Clinical Oncology 34
2016
Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer
Christophe Le Tourneau , Stefan Michiels , Hui K. Gan , Lillian L. Siu
Journal of Clinical Oncology 27 ( 35) 5965 -5971
21
2009
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Jean-Pascal H. Machiels , Lisa Licitra , Danny Rischin , John Waldron
Journal of Clinical Oncology 35
5
2017
Abstract B32: Retrospective correlative study between EGFRvIII, HPV, p16, c‐MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Nicole G. Chau , Bayardo Perez‐Ordonez , Katherine Zhang , Nhu‐An Pham
Molecular Cancer Therapeutics 8
1
2009
Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.
Miguel Quintela-Fandino , Monika Krzyzanowska , Gordon Duncan , Ashley Young
Molecular Cancer Therapeutics 10
2011
Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing.
Janet E. Dancey , Philippe L. Bedard , Suzanne Kamel-Reid , John D. McPherson
Molecular Cancer Therapeutics 10
3
2011
Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
Albiruni RA Razak , Philippe L. Bedard , Benoit You , Devang Panchal
Molecular Cancer Therapeutics 10
2011
Phase 1 trial design: is 3 + 3 the best?
Aaron R. Hansen , Donna M. Graham , Gregory R. Pond , Lillian L. Siu
Cancer Control 21 ( 3) 200 -208
65
2014
A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10‐year outcomes for efficacy and toxicity
Anne W. M. Lee , Stewart Y. Tung , Wai Tong Ng , Victor Lee
Cancer 123 ( 21) 4147 -4157
37
2017
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Yada Kanjanapan , Daphne Day , Lisa Wang , Hamad Al‐Sawaihey
Cancer 125 ( 8) 1341 -1349
124
2019
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
Aaron R. Hansen , Kari Ala‐Leppilampi , Chris McKillop , Lillian L. Siu
Cancer 126 ( 7) 1550 -1558
21
2020
Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Shao Hui Huang , Brian O’Sullivan , Jie Su , Jolie Ringash
Cancer 126 ( 15) 3426 -3437
11
2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Raffit Hassan , Christine Alewine , Idrees Mian , Anna Spreafico
Cancer 126 ( 22) 4936 -4947
4
2020
Determinants of the recommended phase 2 dose of molecular targeted agents
Aaron R Hansen , Natalie Cook , Eitan Amir , Lillian L Siu
Cancer 123 ( 8) 1409 -1415
5
2017
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Jolie Ringash , Heather-Jane Au , Lillian L. Siu , Jeremy D. Shapiro
Cancer 120 ( 2) 181 -189
14
2014
Genomic testing in cancer: patient knowledge, attitudes, and expectations.
Phillip S. Blanchette , Anna Spreafico , Fiona A. Miller , Kelvin Chan
Cancer 120 ( 19) 3066 -3073
46
2014